Clinical trial
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
NCT00003603 · Riverside Haematology Group, Other · Unknown status
Key facts
| NCT number | NCT00003603 |
|---|---|
| Title | Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma |
| Official title | A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma |
| Lead sponsor | Riverside Haematology Group, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | cyclophosphamide, dexamethasone, idarubicin, lomustine, melphalan, prednisolone |
| Enrollment | 660 |
| Start date | Mar 1, 1998 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 20, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: